Literature DB >> 1952866

Emergence of quinolone resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Ontario, Canada.

N Harnett1, S Brown, C Krishnan.   

Abstract

One hundred two isolates of methicillin-resistant Staphylococcus aureus (MRSA) randomly selected from across the Canadian province of Ontario were tested for their susceptibility to ciprofloxacin, norfloxacin, and nalidixic acid by the agar dilution method. Forty-nine percent (50 of 102) had high levels of resistance to these quinolone compounds. For the 50 resistant isolates, ciprofloxacin and norfloxacin had high MICs for 90% of isolates (MIC90s) of 128 micrograms/ml and greater than 128 microgram/ml, respectively; for these isolates, the nalidixic acid MIC90 was greater than 640 micrograms/ml. The majority (98%) of the 50 isolates were also resistant to tobramycin (MIC90, greater than 128 micrograms/ml), while 42% of the isolates were resistant to gentamicin (MIC90, 64 micrograms/ml). Quinolone-resistant MRSA isolates were susceptible to bacteriophages from several groups, indicating independent selection of resistant strains. These results suggest that a reappraisal of the use of fluoroquinolones against MRSA in Canada is necessary.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1952866      PMCID: PMC245290          DOI: 10.1128/AAC.35.9.1911

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus.

Authors:  K Ubukata; N Itoh-Yamashita; M Konno
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 2.  Mechanisms of action of and resistance to ciprofloxacin.

Authors:  D C Hooper; J S Wolfson; E Y Ng; M N Swartz
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

3.  A gentamycin resistance plasmid in Staphylococcus aureus.

Authors:  C J Soussy; D H Bouanchaud; J Fouace; A Dublanchet; J Duval
Journal:  Ann Microbiol (Paris)       Date:  1975 Jul-Aug

4.  Gentamicin-resistant staphylococci as hospital flora: epidemiology and resistance plasmids.

Authors:  R A Weinstein; S A Kabins; C Nathan; H M Sweeney; H W Jaffe; S Cohen
Journal:  J Infect Dis       Date:  1982-03       Impact factor: 5.226

5.  Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors:  I Shalit; S A Berger; A Gorea; H Frimerman
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

6.  Treatment of infections due to methicillin-resistant Staphylococcus aureus.

Authors:  C Watanakunakorn
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

7.  Comparative analysis of conjugative plasmids mediating gentamicin resistance in Staphylococcus aureus.

Authors:  R V Goering; E A Ruff
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

8.  Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations.

Authors:  K E Aldridge; A Janney; C V Sanders
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

9.  Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones.

Authors:  S Schaefler
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

View more
  18 in total

1.  Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.

Authors:  Jessamyn I Perlmutter; Lauren T Forbes; Damian J Krysan; Katherine Ebsworth-Mojica; Jennifer M Colquhoun; Jenna L Wang; Paul M Dunman; Daniel P Flaherty
Journal:  J Med Chem       Date:  2014-10-06       Impact factor: 7.446

Review 2.  The epidemiology of bacterial resistance to quinolones.

Authors:  J F Acar; T F O'Brien; F W Goldstein; R N Jones
Journal:  Drugs       Date:  1993       Impact factor: 9.546

3.  A prospective, randomized study of pefloxacin versus teicoplanin in the treatment of gram-positive coccal infections in cancer patients: early termination due to emergence of resistance to fluoroquinolones.

Authors:  M Aoun; P Van der Auwera; I Varthalitis; A M Bourguignon; M Janssen; D Daneau; F Meunier
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

4.  [Classification and microbiology of osteomyelitis].

Authors:  W Zimmerli; U Flückiger
Journal:  Orthopade       Date:  2004-03       Impact factor: 1.087

5.  Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.

Authors:  J M Entenza; O Marchetti; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

6.  CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; K C Lamp; E M Bailey; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

Review 7.  Mechanisms of quinolone resistance.

Authors:  B Wiedemann; P Heisig
Journal:  Infection       Date:  1994       Impact factor: 3.553

Review 8.  Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.

Authors:  A Dalhoff
Journal:  Infection       Date:  1994       Impact factor: 3.553

9.  sarA inactivation reduces vancomycin-intermediate and ciprofloxacin resistance expression by Staphylococcus aureus.

Authors:  Reena Lamichhane-Khadka; Stephanie A Cantore; James T Riordan; Alejandro Delgado; Alesha E A Norman; Sarah Dueñas; Shahrear Zaman; Sonia Horan; Brian J Wilkinson; John E Gustafson
Journal:  Int J Antimicrob Agents       Date:  2009-03-25       Impact factor: 5.283

Review 10.  Epidemiology of quinolone resistance: Europe and North and South America.

Authors:  F W Goldstein; J F Acar
Journal:  Drugs       Date:  1995       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.